Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial

In this study (n=1133), ponesimod was associated with lower annualised relapse rate (−30.5%), Fatigue Symptom and Impact Questionnaire–Relapsing MS symptom score (−3.57) and combined unique active lesions on magnetic resonance imaging (−56%) compared to teriflunomide.

Source:

JAMA Neurology